Trial reportDaru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences2026
Clinical, humanistic, and economic outcomes of Passiflora alata Curtis use in participants with mild to moderate anxiety: a non-randomized experimental study.
Trial report in Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAnxiety is a disorder treated through psychotherapy and/or pharmacotherapy. Passiflora alata Curtis is a herbal medicine used as a therapeutic alternative, although clinical evidence supporting its effectiveness in anxiety management is limited.
objectivesThis study aimed to evaluate the clinical, humanistic, and economic outcomes in participants with anxiety treated with P. alata extract.
methodsThis was an open-label, non-randomized, before-and-after experimental study. Inclusion criteria were: age ≥ 18 years and anxiety symptoms. The clinical outcome was assessed using the GAD-7 scale, comparing scores between baseline (t0) and the final follow-up (t3). The humanistic outcome was assessed using the TSQM, applied 15 days after treatment initiation and again at t3. The economic outcome consisted of analyzing direct treatment-related costs.
resultsP. alata demonstrated clinical effectiveness in 29 participants (96.7%). TSQM results indicated a perceived improvement in health status within the first weeks. Regarding economic outcomes, differences were observed between the protocols that included P. alata and the conventional treatments offered by the Brazilian Unified Health System.
conclusionIt was concluded that the use of P. alata extract for anxiety management is a potential therapeutic alternative for incorporation into the Brazilian Unified Health System.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.